Medical Oncologist
Understanding your treatment
Abiraterone in Hormone-Sensitive — vs Castration-Resistant Prostate Cancer
Abiraterone is prescribed at two distinct stages of prostate cancer, and the reason it is being given to you depends entirely on which stage you are at. Understanding the difference helps you know what the treatment is trying to do — and what to watch for.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Two different settings — Hormone-sensitive and castration-resistant are distinct phases of the disease, not points on the same scale.
- Same drug, different purpose — Abiraterone is used in both settings, but the goal and the context are not the same.
- Timing matters — Which setting you are in changes what else is prescribed alongside abiraterone and what your oncologist is monitoring.
- Confusion is common — Many patients are unsure which setting applies to them. Asking your oncologist directly is always the right move.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Abiraterone is used in two different situations. In hormone-sensitive prostate cancer, it is added early alongside hormone therapy, before the cancer has adapted to low testosterone. In castration-resistant disease, it is used after that adaptation has occurred. The cancer behaves differently in each phase, and so does the goal of treatment.
What do hormone-sensitive and castration-resistant actually mean?
Hormone-sensitive means the cancer cells are still relying on testosterone to grow. Lowering testosterone with hormone therapy — called ADT, or androgen deprivation therapy — controls the cancer effectively at this stage.
Castration-resistant means the cancer has found ways to keep growing even when testosterone in the blood is at very low levels. It has not become resistant to all treatment. It has changed its biology, and the treatment approach changes with it.
Both stages can involve abiraterone. What differs is why it is being used, what it is expected to achieve, and what is given alongside it.
Which setting applies to you — what to check
- Starting ADT for the first timeYou are in the hormone-sensitive setting. Abiraterone may be prescribed alongside hormone therapy from the beginning.
- Testosterone confirmed at castration levels by blood testA prerequisite your oncologist must confirm before assessing whether the cancer has become castration-resistant.
- PSA rising despite castration-level testosteroneA signal worth reporting promptly — but rising PSA alone does not confirm castration resistance.
- New growth on scans while testosterone is already lowScan-confirmed progression at castration-level testosterone is what establishes castration-resistant disease.
- Abiraterone started alongside your first hormone injection or tabletThis is the hormone-sensitive approach — intensive treatment from the outset.
- Abiraterone added after the cancer progressed on hormone therapyThis is the castration-resistant approach — the treatment responds to a change in the disease.
How abiraterone is used in hormone-sensitive prostate cancer
In this setting, abiraterone is added to ADT before the cancer has had a chance to adapt. The aim is to suppress androgen signalling more completely from the start, rather than waiting to see whether hormone therapy alone is enough.
NCCN and ESMO both include abiraterone as a recommended option in metastatic hormone-sensitive prostate cancer. It is taken daily with a low dose of prednisolone, which helps offset some of abiraterone's effects on fluid balance and blood pressure.
Starting abiraterone at this stage does not mean hormone therapy has failed. It means your oncologist is using a more intensive approach from the beginning, which the clinical evidence supports in eligible patients.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
How abiraterone is used in castration-resistant prostate cancer
When the disease is castration-resistant, the cancer has changed — often by producing its own androgens or amplifying the receptors that respond to them. Abiraterone blocks an enzyme called CYP17, which the cancer uses to keep driving its own growth, including inside the tumour itself.
In this setting, abiraterone is not supplementing an ADT that is still working. It is targeting the pathway the cancer has taken to grow around ADT. Your existing hormone therapy is continued alongside it, because stopping it can allow testosterone from other sources to rise.
NCCN and ESMO include abiraterone as a standard option in metastatic castration-resistant prostate cancer. Your oncologist will have confirmed castration-level testosterone and scan-confirmed progression before making this diagnosis.
How the disease can move from one setting to the other
Metastatic diagnosis
At this point, most prostate cancers are hormone-sensitive. ADT is started, and in eligible patients abiraterone may be added from the beginning as part of an intensified approach.
Monitoring on treatment
PSA levels and scans are reviewed regularly. If PSA is falling and scans are stable, the current approach is working and continues.
PSA begins rising again
A rising PSA while testosterone is at castration levels is a signal that warrants investigation. It is not sufficient on its own to confirm castration resistance.
Scan-confirmed progression
If imaging shows new or growing disease while testosterone is confirmed at castration levels, the disease is reclassified as castration-resistant. This changes the treatment plan.
Reassessment and next steps
If abiraterone was not used in the hormone-sensitive phase, it may now be an option. If it was already used, your oncologist will discuss alternatives based on your tumour biology, overall health, and prior treatment.
Questions patients ask most about these two settings
If I took abiraterone in the hormone-sensitive phase, can I take it again when castration resistance develops?
Generally, no. If abiraterone was used in the hormone-sensitive phase, it is typically not repeated when castration resistance develops, because the cancer is likely to have developed a degree of cross-resistance to it. Your oncologist will consider alternatives, which may include other hormonal agents, chemotherapy with docetaxel or cabazitaxel, or lutetium-PSMA therapy in eligible patients. Which of these is appropriate depends on your overall health, your previous treatment history, and what your scans show.
Does castration-resistant mean the cancer has spread further?
Not necessarily. Castration resistance describes a change in how the cancer behaves biologically — it can grow despite low testosterone — rather than a direct measure of how far it has spread. You can have castration-resistant disease with a similar extent of spread as before. Your oncologist will look at both questions separately: how far the disease has spread and whether the cancer has become castration-resistant are two distinct pieces of information, and a clear answer to both is reasonable to expect.
Why do I keep taking hormone therapy if it is no longer controlling the cancer?
Stopping ADT when the cancer has become castration-resistant can cause testosterone from the testes to rise, which would give the cancer additional fuel to grow. Keeping testosterone at castration levels remains important as a baseline, even though it is no longer sufficient on its own. Abiraterone and similar agents are added on top of continued ADT, not instead of it. Your oncologist will advise on any specific adjustments to your hormone therapy alongside the new treatment.
Is hormone-sensitive disease less serious than castration-resistant disease?
Hormone-sensitive does not mean less serious. It means the cancer is currently responding to a specific type of treatment. Some hormone-sensitive prostate cancers are extensive at diagnosis. What the term tells you is that ADT — alone or with abiraterone — is expected to work at this stage. The goal of adding abiraterone early in the hormone-sensitive setting is to maintain disease control for as long as possible and delay the development of resistance.
Does everyone with metastatic prostate cancer eventually reach castration resistance?
Over time, a large proportion of patients on ADT do develop castration resistance, but the timeline varies considerably between individuals and cannot be reliably predicted at diagnosis. Some patients remain in the hormone-sensitive phase for many years. Approaches that combine agents like abiraterone with ADT from the beginning are intended in part to delay resistance. We do not yet fully understand which factors predict who will develop resistance sooner, and your oncologist cannot give a precise individual timeline.
Do I take abiraterone differently depending on which setting I am in?
The tablet and the low-dose prednisolone prescribed with it are the same in both settings — taken once daily on an empty stomach. What differs is what else is given alongside it and what your oncologist is monitoring for. In the hormone-sensitive setting, ADT is still actively suppressing testosterone and is expected to be working. In the castration-resistant setting, ADT continues but the monitoring shifts to watching for further progression and measuring the cancer's response to abiraterone. Follow your oncologist's specific instructions rather than comparing with what another patient was told.
Explore 50 more Prostate Cancer Targeted Medicines topics
Drug Deep Dive: Abiraterone (Zytiga)
- Abiraterone (Zytiga, Abirapro, Abretone): The Complete Patient Guide
- Abiraterone Interactions: Steroids, BP Medicines and Herbal Products
- Abiraterone Myths: Steroids, Weight Gain and 'It Stops Working Fast'
- Abiraterone Price in India: Brand, Generic and Monthly Cost
- Abiraterone Side Effects: The Complete List and Timeline
- Abiraterone Success Rate and Survival: An Honest Look at the Numbers
- Abiraterone With ADT, Docetaxel and Radiation: Your Full Regimen Explained
- Abiraterone in Elderly Patients and Those With Other Illnesses
- Abiraterone in Hormone-Sensitive vs Castration-Resistant Prostate Cancer
- Abiraterone vs Enzalutamide: How to Choose in Prostate Cancer
- Diet and Nutrition While on Abiraterone
- Fatigue, Hot Flushes and Joint Pain on Abiraterone
- Fertility, Pregnancy and Contraception on Abiraterone
- How Does Abiraterone Work? The CYP17 Inhibitor Explained
- How Long Does Abiraterone Take to Work?
- How Long Will You Stay on Abiraterone?
- Liver Enzyme Rises on Abiraterone: Why the First Three Months Matter Most
- Swelling, Low Potassium and High Blood Pressure on Abiraterone
- Tests and Monitoring While You Are on Abiraterone
- When Abiraterone Stops Working: Resistance and What Comes Next
- Who Is Eligible for Abiraterone? Advanced and Metastatic Prostate Cancer
- Why Abiraterone Is Always Given With Prednisolone
- Why Abiraterone Must Be Taken on an Empty Stomach
- Will Insurance or a Government Scheme Pay for Abiraterone?
- Work, Travel and Daily Life on Abiraterone
Drug Deep Dive: Enzalutamide (Xtandi)
- Diet and Nutrition While on Enzalutamide
- Dizziness, Falls and Seizure Risk on Enzalutamide
- Does Enzalutamide Need a Steroid? Why It Differs From Abiraterone
- Enzalutamide (Xtandi, Bdenza, Enzamide): The Complete Patient Guide
- Enzalutamide Interactions: Blood Thinners, Statins and Seizure-Threshold Drugs
- Enzalutamide Myths: 'It's Chemotherapy', Fatigue and Loss of Masculinity
- Enzalutamide Price in India: Brand, Generic and Monthly Cost
- Enzalutamide Side Effects: The Complete List and Timeline
- Enzalutamide Success Rate and Survival: An Honest Look at the Numbers
- Enzalutamide With ADT and Other Prostate Cancer Treatments
- Enzalutamide in Elderly Patients and Those With Other Illnesses
- Enzalutamide in Non-Metastatic vs Metastatic Prostate Cancer
- Enzalutamide vs Abiraterone vs Apalutamide: Choosing an AR Inhibitor
- Fertility, Pregnancy and Contraception on Enzalutamide
- How Does Enzalutamide Work? The Androgen Receptor Signalling Inhibitor Explained
- How Long Does Enzalutamide Take to Work?
- How Long Will You Stay on Enzalutamide?
- Memory, Concentration and Blood Pressure Changes on Enzalutamide
- Severe Fatigue on Enzalutamide: The Commonest Reason Men Stop
- Taking Enzalutamide: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Enzalutamide
- When Enzalutamide Stops Working: Resistance and What Comes Next
- Who Is Eligible for Enzalutamide? Advanced and Metastatic Prostate Cancer
- Will Insurance or a Government Scheme Pay for Enzalutamide?
- Work, Travel and Daily Life on Enzalutamide
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
My oncologist said my testosterone is 'at castration levels'. What does that mean?
Castration levels means your testosterone has been reduced to a very low level — the level that would historically have been reached through surgical removal of the testes, which is the reference point the term comes from. Hormone therapy (ADT) achieves this without surgery. Your oncologist confirms it with a blood test. This measurement is the starting point for any assessment of whether your cancer is still hormone-sensitive or has become castration-resistant — without confirming it, neither diagnosis can be made accurately.
Can the cancer become castration-resistant while I am already taking abiraterone in the hormone-sensitive phase?
Yes, it can. Abiraterone in the hormone-sensitive setting aims to delay resistance, not permanently prevent it. If your PSA begins rising again while you are on treatment, your oncologist will investigate. Rising PSA alone is not enough to confirm castration resistance — imaging showing new or growing disease while testosterone remains at castration levels is needed. If resistance does develop, your oncologist will discuss what the next treatment step looks like based on your specific situation and what you have already received.
My PSA fell after starting treatment but is now rising again. Does that mean I am castration-resistant?
A rising PSA after an initial fall is a signal worth investigating, but it does not confirm castration resistance on its own. Your oncologist will check your testosterone level first — if testosterone has risen, the hormone therapy may need adjustment rather than the diagnosis changing. Castration resistance requires both confirmed castration-level testosterone and scan-confirmed progression. Do not wait until your next scheduled visit if PSA has clearly increased — contact your team so they can assess it promptly rather than watching it continue to rise.
Do I take abiraterone the same way in both settings?
Yes — the tablet and the low-dose prednisolone taken with it are the same in both settings. The practical difference is in what else is prescribed alongside abiraterone and what your team is watching for at each visit. One thing that does not change regardless of setting: abiraterone must be taken on an empty stomach. Food significantly increases how much of the drug your body absorbs, which can affect both how well it works and how strong the side effects are. Your oncologist's specific instructions for your situation take precedence over anything else you read.
If I have castration-resistant disease, does that mean I have run out of treatment options?
No. Castration-resistant prostate cancer has several recommended treatment options. Depending on your prior treatment, your oncologist may consider other hormonal agents, chemotherapy, lutetium-PSMA therapy in eligible patients, or clinical trials. NCCN and ESMO guidelines address multiple lines of treatment for castration-resistant disease. The reclassification means the treatment plan needs to change — not that the options have been exhausted. Being clear about which treatments you have already received helps your oncologist identify what is appropriate next.
Should I ask for a second opinion if I am uncertain which setting I am in?
A second opinion is always reasonable when you are uncertain about a diagnosis or treatment plan, and most oncologists support the request. Before seeking one, start by asking your own oncologist to explain the specific evidence they used: what your testosterone level showed, what the scans showed, and why they chose this treatment at this point in time. A clear answer to those three questions is reasonable to expect, and it often resolves the uncertainty without needing a referral. If it does not, a second opinion at a centre experienced in prostate cancer is a legitimate next step.